查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607983

肝炎治疗药物市场：按类型、药物类别、分销管道划分 - 全球预测 2025-2030

Hepatitis Therapeutics Market by Type (Hepatitis A, Hepatitis B, Hepatitis C), Drug Class (Immune Modulator, Oral Antiviral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肝炎治疗药物市值为291.9亿美元，预计2024年将达到307.6亿美元，复合年增长率为4.11%，到2030年将达到387.1亿美元。

肝炎药物市场主要包括用于管理和治癒各种肝炎类型（包括甲型、乙型、丙型、丁型和戊型肝炎）的治疗方法的开拓、分销和应用。其范围包括抗病毒药物、疫苗、免疫系统调节剂以及对抗这些病毒引起的肝臟感染疾病所必需的支持性护理。肝炎药物的需求源自于世界肝臟疾病的负担，这些疾病常导致肝硬化和癌症等严重併发症，需要有效的治疗。由于肝炎病毒在世界各地广泛流行，肝炎药物的应用范围很广，包括医院、诊所和专科治疗中心，其最终用途目标是已开发地区和发展中地区。

主要市场统计
基准年[2023] 291.9亿美元
预计年份 [2024] 307.6亿美元
预测年份 [2030] 387.1亿美元
复合年增长率（%） 4.11%

市场开拓受到以下因素的显着影响：对肝炎的认识提高、高效抗病毒药物的开发、政府扩大疫苗接种计划的努力以及诊断工具可用性的增加。药物配方和药物传输系统的技术进步对于推动市场需求也至关重要。然而，高昂的治疗成本、严格的监管要求以及不断出现的病毒突变等限制，尤其是在低收入地区，对市场扩张构成了挑战。机会包括扩大疫苗研究以涵盖更多病毒株、开发适合资源匮乏环境的经济有效的治疗方法，以及利用数位医疗技术实现更好的管理和患者依从性。创新的治疗领域包括新颖的治疗层级、根据个人遗传特征量身定制治疗的个人化医疗方法，以及开髮长效注射剂以提高依从性和结果。

为了利用这些商机，企业应专注于与研究机构建立策略联盟，增加研发投入，并进入患病率高但临床需求未满足的开拓地区。市场格局瞬息万变，製药巨头和生技公司为了透过药物开发突破站稳脚步而展开激烈竞争，这既充满挑战，又为创新提供了肥沃的土壤。

市场动态：揭示快速发展的肝炎药物市场的关键市场洞察

供需的动态交互作用正在改变肝炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 老年人口肝炎负担增加
    • 政府积极努力治疗肝炎
    • 扩大医疗基础设施
  • 市场限制因素
    • 肝炎治疗药物和诊断费用高昂
  • 市场机会
    • 介绍根除肝炎的创新
    • 肝炎治疗药物的持续研发活动
  • 市场挑战
    • 与肝炎治疗药物相关的副作用

波特五力：驾驭肝炎药物市场的策略工具

波特的五力框架是了解肝炎药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肝炎药物市场的外部影响

外部宏观环境因素在塑造肝炎治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肝炎治疗药物市场的竞争状况

肝炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肝炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估肝炎治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

肝炎药物市场的策略分析和成功的推荐途径

对于旨在加强在全球市场的影响力的公司来说，对肝炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人肝炎负担增加
      • 政府首选的肝炎治疗方法
      • 扩大医疗基础设施
    • 抑制因素
      • 肝炎药物和诊断费用高昂
    • 机会
      • 介绍根除肝炎的创新
      • 正在进行的肝炎治疗研究和开发活动
    • 任务
      • 与肝炎药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肝炎治疗药物市场：依类型

  • 甲型肝炎
  • B型肝炎
  • C型肝炎

第七章依药物类别分類的肝炎治疗药物市场

  • 免疫调节剂
  • 口服抗病毒药物

第八章肝炎治疗药物市场：按分销管道

  • 药局
  • 在线的
  • 药局

第九章 北美及南美肝炎药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区肝炎药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的肝炎药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Avantor Inc.
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • FUJIREBIO Inc.
  • Gilead Sciences, Inc.
  • Grifols SA
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Ortho Clinical Diagnostics
  • Quest Diagnostics Incorporated
Product Code: MRR-450A0628DE07

The Hepatitis Therapeutics Market was valued at USD 29.19 billion in 2023, expected to reach USD 30.76 billion in 2024, and is projected to grow at a CAGR of 4.11%, to USD 38.71 billion by 2030.

The hepatitis therapeutics market encompasses the development, distribution, and application of medical treatments aimed at managing and curing various forms of hepatitis, primarily hepatitis A, B, C, D, and E. Its scope includes antiviral medications, vaccines, immune system modulators, and supportive care options vital in combating liver infections caused by these viruses. The necessity for hepatitis therapeutics arises from the global burden of liver diseases, which often lead to severe complications like liver cirrhosis and cancer, necessitating effective treatments. Hepatitis therapies find applications across hospitals, clinics, and specialized treatment centers, with end-use targeting both developed and developing regions due to the widespread prevalence of hepatitis strains worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 29.19 billion
Estimated Year [2024] USD 30.76 billion
Forecast Year [2030] USD 38.71 billion
CAGR (%) 4.11%

Market growth is significantly influenced by factors such as rising awareness of hepatitis conditions, the development of highly effective antiviral drugs, governmental initiatives for widespread immunization programs, and the increased availability of diagnostic tools. Technological advancements in drug formulation and delivery systems are also pivotal in driving market demand. However, limitations such as the high cost of treatment, especially in low-income regions, stringent regulatory requirements, and the emergence of virus mutations challenge market expansion. Opportunities exist in expanding research on vaccines to cover more viral strains, developing cost-effective therapies suitable for low-resource settings, and leveraging digital health technologies for better management and patient compliance. Innovative areas for exploration include novel therapeutic classes, personalized medicine approaches that tailor treatment based on individual genetic profiles, and development of long-acting injectables for better adherence and outcomes.

To exploit these opportunities, businesses should focus on strategic collaborations with research institutions, enhanced investment in R&D, and pursuing market entry into untapped regions with high disease prevalence yet unmet clinical needs. The nature of the market is dynamic, with increasing competition among pharmaceutical giants and biotech firms striving to secure a foothold through breakthroughs in drug development, creating both a challenging landscape and a fertile ground for innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatitis Therapeutics Market

The Hepatitis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising burden of hepatitis in geriatric population
    • Favorable government initiatives for hepatitis treatment
    • Expanding healthcare infrastructure
  • Market Restraints
    • High cost of hepatitis therapeutics and diagnosis
  • Market Opportunities
    • Introduction to innovations in hepatitis elimination
    • Ongoing research and development activities for hepatitis therapeutics
  • Market Challenges
    • Associated side effects of hepatitis therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Hepatitis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatitis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatitis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatitis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatitis Therapeutics Market

A detailed market share analysis in the Hepatitis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatitis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatitis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatitis Therapeutics Market

A strategic analysis of the Hepatitis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Bristol-Myers Squibb Company, DiaSorin S.p.A., F. Hoffmann-La Roche AG, FUJIREBIO Inc., Gilead Sciences, Inc., Grifols S.A., Johnson & Johnson Services Inc, Merck & Co., Inc., Ortho Clinical Diagnostics, and Quest Diagnostics Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hepatitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Hepatitis A, Hepatitis B, and Hepatitis C.
  • Based on Drug Class, market is studied across Immune Modulator and Oral Antiviral.
  • Based on Distribution Channel, market is studied across Drug Stores, Online, and Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of hepatitis in geriatric population
      • 5.1.1.2. Favorable government initiatives for hepatitis treatment
      • 5.1.1.3. Expanding healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of hepatitis therapeutics and diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction to innovations in hepatitis elimination
      • 5.1.3.2. Ongoing research and development activities for hepatitis therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Associated side effects of hepatitis therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hepatitis Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Hepatitis A
  • 6.3. Hepatitis B
  • 6.4. Hepatitis C

7. Hepatitis Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Immune Modulator
  • 7.3. Oral Antiviral

8. Hepatitis Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. Online
  • 8.4. Pharmacies

9. Americas Hepatitis Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hepatitis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Avantor Inc.
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Bristol-Myers Squibb Company
  • 7. DiaSorin S.p.A.
  • 8. F. Hoffmann-La Roche AG
  • 9. FUJIREBIO Inc.
  • 10. Gilead Sciences, Inc.
  • 11. Grifols S.A.
  • 12. Johnson & Johnson Services Inc
  • 13. Merck & Co., Inc.
  • 14. Ortho Clinical Diagnostics
  • 15. Quest Diagnostics Incorporated

LIST OF FIGURES

  • FIGURE 1. HEPATITIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEPATITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEPATITIS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023